Search Results

There are 7987611 results for: content related to: Erratum: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases

  1. You have free access to this content
    Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases

    Cancer

    Volume 115, Issue 15, 1 August 2009, Pages: 3571–3580, Johnny Kao, Stuart Packer, Ha Linh Vu, Myron E. Schwartz, Max W. Sung, Richard G. Stock, Yeh-Chi Lo, Delphine Huang, Shu-Hsia Chen and Jamie A. Cesaretti

    Version of Record online : 17 JUN 2009, DOI: 10.1002/cncr.24412

  2. You have free access to this content
    Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

    International Journal of Cancer

    Volume 130, Issue 8, 15 April 2012, Pages: 1948–1959, Benedetto Farsaci, Jack P. Higgins and James W. Hodge

    Version of Record online : 8 AUG 2011, DOI: 10.1002/ijc.26219

  3. You have full text access to this OnlineOpen article
    Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

    Journal of Cellular and Molecular Medicine

    Volume 19, Issue 2, February 2015, Pages: 430–441, Eva Juengel, Dana Kim, Jasmina Makarević, Michael Reiter, Igor Tsaur, Georg Bartsch, Axel Haferkamp and Roman A. Blaheta

    Version of Record online : 2 DEC 2014, DOI: 10.1111/jcmm.12471

  4. You have full text access to this OnlineOpen article
    Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction

    Cancer Medicine

    Volume 4, Issue 7, July 2015, Pages: 1003–1015, Esther A. Kleibeuker, Matthijs A. ten Hooven, Kitty C. Castricum, Richard Honeywell, Arjan W. Griffioen, Henk M. Verheul, Ben J. Slotman and Victor L. Thijssen

    Version of Record online : 31 MAR 2015, DOI: 10.1002/cam4.441

  5. You have full text access to this OnlineOpen article
    Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment

    Cancer Science

    Volume 106, Issue 2, February 2015, Pages: 160–170, Gökçe Hatipoglu, Stefan W. Hock, Ruth Weiss, Zheng Fan, Tina Sehm, Ali Ghoochani, Michael Buchfelder, Nicolai E. Savaskan and Ilker Y. Eyüpoglu

    Version of Record online : 15 FEB 2015, DOI: 10.1111/cas.12580

  6. You have free access to this content
    PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma-cell lines

    International Journal of Cancer

    Volume 131, Issue 2, 15 July 2012, Pages: E45–E55, Claus Bender and Axel Ullrich

    Version of Record online : 28 FEB 2012, DOI: 10.1002/ijc.26486

  7. You have free access to this content
    Sunitinib-induced hyperparathyroidism

    Cancer

    Volume 118, Issue 12, 15 June 2012, Pages: 3165–3172, Valentina Baldazzi, Renato Tassi, Alberto Lapini, Alice Lunghi, Eleonora Garofoli, Salvatore Caruso, Marco Carini and Roberto Mazzanti

    Version of Record online : 28 SEP 2011, DOI: 10.1002/cncr.26435

  8. You have free access to this content
    Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy

    International Journal of Cancer

    Volume 134, Issue 7, 01 April 2014, Pages: 1695–1705, Ritika Jaini, Patricia Rayman, Peter A. Cohen, James H. Finke and Vincent K. Tuohy

    Version of Record online : 8 OCT 2013, DOI: 10.1002/ijc.28488

  9. You have free access to this content
    Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders

    British Journal of Pharmacology

    Volume 171, Issue 24, December 2014, Pages: 5757–5773, Wolf Wrasidlo, Leslie A Crews, Igor F Tsigelny, Emily Stocking, Valentina L Kouznetsova, Diana Price, Amy Paulino, Tania Gonzales, Cassia R Overk, Christina Patrick, Edward Rockenstein and Eliezer Masliah

    Version of Record online : 1 DEC 2014, DOI: 10.1111/bph.12875

  10. You have free access to this content
    Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

    Cancer

    Volume 120, Issue 5, 1 March 2014, Pages: 692–701, Petros D. Grivas, Stephanie Daignault, Scott T. Tagawa, David M. Nanus, Walter M. Stadler, Robert Dreicer, Manish Kohli, Daniel P. Petrylak, David J. Vaughn, Kathryn A. Bylow, Steven G. Wong, Joseph L. Sottnik, Evan T. Keller, Mahmoud Al-Hawary, David C. Smith and Maha Hussain

    Version of Record online : 18 NOV 2013, DOI: 10.1002/cncr.28477

  11. You have free access to this content
    Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662

    British Journal of Clinical Pharmacology

    Volume 79, Issue 5, May 2015, Pages: 809–819, Huixin Yu, Neeltje Steeghs, Jacqueline S. L. Kloth, Djoeke de Wit, J. G. Coen van Hasselt, Nielka P. van Erp, Jos H. Beijnen, Jan H. M. Schellens, Ron H. J. Mathijssen and Alwin D. R. Huitema

    Version of Record online : 22 APR 2015, DOI: 10.1111/bcp.12550

  12. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells

    The Prostate

    Volume 75, Issue 11, August 1, 2015, Pages: 1137–1149, Roque Diaz, Paul A. Nguewa, Miriam Redrado, Irene Manrique and Alfonso Calvo

    Version of Record online : 20 APR 2015, DOI: 10.1002/pros.22980

  13. You have free access to this content
    Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease

    Arthritis & Rheumatism

    Volume 64, Issue 6, June 2012, Pages: 1990–2000, Niloufar Kavian, Amélie Servettaz, Wioleta Marut, Carole Nicco, Christiane Chéreau, Bernard Weill and Frédéric Batteux

    Version of Record online : 25 MAY 2012, DOI: 10.1002/art.34354

  14. You have full text access to this Open Access content
    Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene

    Cancer Science

    Volume 101, Issue 6, June 2010, Pages: 1493–1500, Haruka Kawahara, Kohji Noguchi, Kazuhiro Katayama, Junko Mitsuhashi and Yoshikazu Sugimoto

    Version of Record online : 22 FEB 2010, DOI: 10.1111/j.1349-7006.2010.01539.x

  15. You have free access to this content
    Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model

    Hepatology

    Volume 55, Issue 1, January 2012, Pages: 141–152, Diego M. Avella, Guangfu Li, Todd D. Schell, Dai Liu, Samuel Shao-Min Zhang, Xi Lou, Arthur Berg, Eric T. Kimchi, Hephzibah Rani S. Tagaram, Qing Yang, Serene Shereef, Luis S. Garcia, Mark Kester, Harriet C. Isom, C. Bart Rountree and Kevin F. Staveley-O'Carroll

    Version of Record online : 21 DEC 2011, DOI: 10.1002/hep.24652

  16. You have free access to this content
    Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

    Cancer

    Volume 118, Issue 5, 1 March 2012, Pages: 1252–1259, Carlos H. Barrios, David Hernandez-Barajas, Michael P. Brown, Se-Hoon Lee, Luis Fein, Jin-Hwang Liu, Subramanian Hariharan, Bridget A. Martell, Jinyu Yuan, Akintunde Bello, Zhixiao Wang, Rajiv Mundayat and Sun-Young Rha

    Version of Record online : 6 SEP 2011, DOI: 10.1002/cncr.26440

  17. You have free access to this content
    Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

    International Journal of Cancer

    Volume 130, Issue 1, 1 January 2012, Pages: 223–233, Seng Chuan Tang, Jurjen S. Lagas, Nienke A.G. Lankheet, Birk Poller, Michel J. Hillebrand, Hilde Rosing, Jos H. Beijnen and Alfred H. Schinkel

    Version of Record online : 7 APR 2011, DOI: 10.1002/ijc.26000

  18. You have free access to this content
    Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation

    BJU International

    Volume 112, Issue 2, July 2013, Pages: E211–E220, Iori Sakai, Hideaki Miyake and Masato Fujisawa

    Version of Record online : 10 JAN 2013, DOI: 10.1111/j.1464-410X.2012.11655.x

  19. Sunitinib–ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently

    Fundamental & Clinical Pharmacology

    Volume 29, Issue 4, August 2015, Pages: 404–416, Christine Li Ling Lau, Sook Tyng Chan, Manimegahlai Selvaratanam, Hui Wen Khoo, Adeline Yi Ling Lim, Pilar Modamio, Eduardo L. Mariño and Ignacio Segarra

    Version of Record online : 7 JUN 2015, DOI: 10.1111/fcp.12126

  20. You have free access to this content
    Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience

    Asia-Pacific Journal of Clinical Oncology

    Volume 8, Issue 2, June 2012, Pages: 132–144, Aiping ZHOU

    Version of Record online : 24 APR 2012, DOI: 10.1111/j.1743-7563.2012.01525.x